ArticlePediatric research2026
Trimester of maternal SARS-CoV-2 infection differentially predicts newborn size in the COVID-19 Mother Baby Outcomes (COMBO) cohort.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundIn-utero exposures affect the developing fetus differentially and may manifest as growth and body size differences. We examined associations between maternal SARS-CoV-2 infection and newborn body size at a large medical center in New York City.
methodsBetween 3/22/2020 and 10/31/2020, birth outcomes for 544 newborns exposed to SARS-CoV-2 in utero and 3325 unexposed newborns were collected through retrospective chart review as part of the COVID-19 Mother Baby Outcomes (COMBO) Initiative. Data were also abstracted for 560 newborns born in February 2020 as a pre-pandemic comparison group. Growth outcomes at 6-10 weeks of life were available for a subset of 865 newborns followed in our hospital system.
resultsNewborns exposed to SARS-CoV-2 during the first trimester had significantly smaller birth weight, length, head circumference (HC) and earlier gestational age (GA) at birth than unexposed or second-to-third trimester exposed newborns. Mediation analysis found that GA mediated the relationship between first trimester SARS-CoV-2 exposure and body size at birth.
conclusionMaternal SARS-CoV-2 infection during the first trimester is associated with smaller body size at birth and this association is largely mediated by earlier GA. Size differences at birth can predict later adverse cardiometabolic and neurodevelopmental outcomes, warranting prospective analysis in this cohort. IMPACT: Using data obtained through universal SARS-CoV-2 testing at a large, urban medical center, maternal SARS-CoV-2 infection during pregnancy was associated with newborn size. Previous literature shows that SARS-CoV-2 does not tend to cause severe respiratory disease in infants and that vertical transmission to the fetus is unlikely. However, maternal SARS-CoV-2 infection during pregnancy is associated with increased occurrence of pre-term delivery. This study contributes to the literature by showing that timing of maternal SARS-CoV-2 infection, specifically during the first trimester of pregnancy, predicts smaller newborn body size and that this relationship is mediated by earlier gestational age (GA) at birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.